Currently, a phase II/III study is evaluating the safety and efficacy of intravitreal injection of sepofarsen, an RNA antisense oligonucleotide, in LCA patients with a specific CEP290 mutation [36] (NCT03913143). The gene discussed is CEP290; the disease is Leber congenital amaurosis.